Cytokinetics, Incorporated (CYTK) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à South San Francisco, CA, United States. Le PDG actuel est Robert I. Blum.
CYTK a date d'introduction en bourse 2004-04-30, 498 employés à temps plein, cotée sur le NASDAQ Global Select, une capitalisation boursière de $8.17B.
Cytokinetics, Incorporated is a late-stage biopharmaceutical company dedicated to discovering, developing, and commercializing small molecule drugs that modulate muscle function and contractility to treat debilitating diseases. The company's pipeline includes omecamtiv mecarbil, a cardiac myosin activator in Phase III trials for heart failure, and reldesemtiv, a skeletal muscle troponin activator in Phase III development for amyotrophic lateral sclerosis and spinal muscular atrophy. Additional candidates in development include aficamten, a cardiac myosin inhibitor in Phase III trials for obstructive hypertrophic cardiomyopathy, alongside earlier-stage programs such as CK-136 and CK-3772271. Founded in 1997 and headquartered in South San Francisco, California, Cytokinetics maintains a strategic alliance with Astellas Pharma Inc. to advance its muscle-focused therapeutic platform.
